news are coming!! buyout closer than you think, dont listen to the whinners, same story as LOGC, tomorrow we can wake up with acquisition price at $1.50 easily, follow the market not the whinners
bandolero2007
Posts
-
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
-
cheaper?
-
now what?
-
volume too low
-
is this a joke? just last week this stock was at 42, PT should be $150, $170, but $42?
-
support at 10, it is melting like a popsicle in miami beach, i am a bagholder without powder to average down but it is fair to recognize that this shit is sinking like the titanic, dont follow the pumpers screaming “” buy the dips””, they dont even know where it is dipping now, this is not the bottom, tomorrow expect 15, historical support at 12 and it is heading to test it once again, good luck
-
blame the BOT, not the human, there is not enough day trader either sellers or buyers to bring this stock this down day after day, it is the machine that runs WS and make richer more richer, we need to play same game as them
-
it is non stop bleeding, lower resistance was broken, finding new support above 20 but market is hedious, I am all in and losing but not selling, only way to be defeated is when you sale for a loss, so as long as you keep your shares you win in the long run
-
low volume is dragging this monster down
-
it’s been same pattern for a week, around 150K volume by end of the day and downtrend behavior, same thing happened 2 weeks ago and then it jumped to 40 without any PR, weird!!!
-
earning report is on 3/25 pre market
-
price in frankfurt is $8.59, 🥺
-
Is AIKI stock a buy?
The best way to assess whether AIKI stock may be a good investment is to look at its target market. The global cancer therapeutics market is on course to exceed $180 billion a year by 2026 from $98.9 billion in 2018. Currently, AIkido Pharma is a low-cost ticket for investors seeking exposure to the lucrative cancer treatment market.
With fierce big pharma competition in the cancer market, it wouldn’t be surprising if AIkido Pharma becomes an acquisition target for industry giants. The company’s modest market capitalization of less than $40 million makes it an easy buyout target. A buyout could open a lucrative exit for AIKI stock investors.
-
AIkido Pharma Inc. (NASDAQ:AIKI) Shares Look Bullish in 2021
-
AIkido Pharma Inc. (AIKI)’s beta value is 1.62, and its average true range (ATR) is 0.28. The company’s stock has been forecasted to trade at an average price of $1802.25 over the course of the next 52 weeks, with a low of $1802.25 and a high of $1802.25. Based on these price targets, the low is 136434.09 off current price, whereas the price has to move +136434.09% to reach the yearly target high. Additionally, analysts’ median price of $1802.25 is likely to be welcomed by investors because it represents an increase of +136434.09% from the current levels.
-
HERE COMES $100
-
why selling @ 97 when you can hold 2 more days at profit from $150?
-
they should release USA PHASE 3 anytime now, we should hit $100 before news, $150 after!!
-
highway to $100 is clear today, not speed limit enforced!!
ADMP
ALT
CMMB
CMMB
CMMB
CMMB
CMMB
CMMB
CMMB
CMMB
CMMB
PULM
OCGN
AIKI
AIKI
AIKI
NVAX
NVAX
NVAX
NVAX